12 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
International Conference on Molecular Targets and Cancer Therapeutics and at the 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC).
YUSIMRY™
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
at the American Society of Clinical Oncology annual meeting in June demonstrated a statistically significant and clinically meaningful improvement in overall
424B3
CHRS
Coherus Biosciences Inc
26 Jul 23
Prospectus supplement
4:59pm
in patients with HCC and non-small-cell lung cancer (“NSCLC”), in April 2022. In June 2022, at the 2022 American Society of Clinical Oncology (“ASCO … in global cancer immunotherapy networks such as the Society of Immunotherapy for Cancer (SITC) and ASCO. Dr. Ibrahim studied medicine and medical oncology
S-4/A
CHRS
Coherus Biosciences Inc
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
, at the 2022 American Society of Clinical Oncology (“ASCO”), Annual Meeting, Surface presented initial Phase 1/1b data demonstrating clinical … . (Nasdaq: BLUE). Dr. Ibrahim is actively involved in global cancer immunotherapy networks such as the Society of Immunotherapy for Cancer (SITC
S-4
CHRS
Coherus Biosciences Inc
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
. In June 2022, at the 2022 American Society of Clinical Oncology (“ASCO”), Annual Meeting, Surface presented initial Phase 1/1b data demonstrating clinical … , Inc. (Nasdaq: BLUE). Dr. Ibrahim is actively involved in global cancer immunotherapy networks such as the Society of Immunotherapy for Cancer (SITC
8-K
EX-99.1
li9chdenuqka g9hdu2u
5 Aug 21
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:06pm
10-K
1dx1 n85kfs6p8wdifd8
23 Mar 15
Annual report
12:00am
424B4
8xg5vi1qq1qtyd
6 Nov 14
Prospectus supplement with pricing info
12:00am
S-1/A
so55yp3
6 Oct 14
IPO registration (amended)
12:00am
DRS/A
tubkqt
15 Sep 14
Draft registration statement (amended)
12:00am
DRS
9v2n12c8 5k8j
4 Aug 14
Draft registration statement
12:00am
- Prev
- 1
- Next